562 related articles for article (PubMed ID: 25404321)
1. Structures of protective antibodies reveal sites of vulnerability on Ebola virus.
Murin CD; Fusco ML; Bornholdt ZA; Qiu X; Olinger GG; Zeitlin L; Kobinger GP; Ward AB; Saphire EO
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17182-7. PubMed ID: 25404321
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.
Davidson E; Bryan C; Fong RH; Barnes T; Pfaff JM; Mabila M; Rucker JB; Doranz BJ
J Virol; 2015 Nov; 89(21):10982-92. PubMed ID: 26311869
[TBL] [Abstract][Full Text] [Related]
4. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
[TBL] [Abstract][Full Text] [Related]
5. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
[TBL] [Abstract][Full Text] [Related]
6. Tobacco against Ebola virus disease.
Budzianowski J
Przegl Lek; 2015; 72(10):567-71. PubMed ID: 26946569
[TBL] [Abstract][Full Text] [Related]
7. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
[TBL] [Abstract][Full Text] [Related]
8. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding.
Ripoll DR; Mitchell DAJ; Dupuy LC; Wallqvist A; Schmaljohn C; Chaudhury S
Hum Vaccin Immunother; 2017 Dec; 13(12):2953-2966. PubMed ID: 28922082
[TBL] [Abstract][Full Text] [Related]
10. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
Murin CD; Gilchuk P; Crowe JE; Ward AB
Front Immunol; 2021; 12():808047. PubMed ID: 35082794
[TBL] [Abstract][Full Text] [Related]
11. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
[TBL] [Abstract][Full Text] [Related]
12. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
[TBL] [Abstract][Full Text] [Related]
14. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
[TBL] [Abstract][Full Text] [Related]
15. Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.
Frei JC; Nyakatura EK; Zak SE; Bakken RR; Chandran K; Dye JM; Lai JR
Sci Rep; 2016 Jan; 6():19193. PubMed ID: 26758505
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE
Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037
[TBL] [Abstract][Full Text] [Related]
17. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.
Nyakatura EK; Zak SE; Wec AZ; Hofmann D; Shulenin S; Bakken RR; Aman MJ; Chandran K; Dye JM; Lai JR
J Biol Chem; 2018 Apr; 293(16):6201-6211. PubMed ID: 29500195
[TBL] [Abstract][Full Text] [Related]
18. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
[TBL] [Abstract][Full Text] [Related]
19. [The use of monoclonal antibodies for the treatment of Ebola virus disease.].
Sizikova TE; Borisevich GV; Shcheblyakov DV; Burmistrova DA; Lebedev VN
Vopr Virusol; 2018; 63(6):245-249. PubMed ID: 30641019
[TBL] [Abstract][Full Text] [Related]
20. The ongoing evolution of antibody-based treatments for Ebola virus infection.
Mendoza EJ; Racine T; Kobinger GP
Immunotherapy; 2017 Mar; 9(5):435-450. PubMed ID: 28357917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
